This could be partly attributed to an increase in focus on using RNA-based therapies for rare disease treatment.

PEMGARDA (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 millionPreliminary Q4 2024 total operating costs and expenses of approximately ...

The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market research report.Rockville, MD, Feb. 03, 2025 (GLOBE ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

The Nation Newspaper 'Underage mothers, diseases, delayed healthcare access contributing to maternal mortality in Nigeria' ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Sue VanWassenhove’s adult children got her a smartwatch to track her health after she fell a couple times.Fiddling wit ...

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

My primary care physician has been using an AI-assisted device during our office visits that transcribes and records our ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

The Infectious diseases topic features the latest news, guidelines, education, EMS training and tips related to infection control and EMS role in prevention the transmission of and caring for ...

identifying the cognitive-behavioral syndrome based on specific symptoms, and determining the likely brain diseases or conditions causing the symptoms.